Insulin Icodec, a rising star in insulin therapy, is an ultra-long-acting basal insulin. It has been approved in countries and regions including Canada, Japan, Australia, China, and the European Union for the treatment of type 2 diabetes mellitus (T2DM) in adults.
Findings from multicenter studies indicate that Insulin Icodec demonstrates excellent performance in glycemic control stability among adult patients with type 2 diabetes mellitus (T2DM). Its hypoglycemic effect is non-inferior to that of daily-dosed basal insulin. Some study results suggest that the reduction in glycated hemoglobin (HbA1c) in the Insulin Icodec group is superior to that achieved with daily-dosed basal insulin formulations.